Oncology (all articles)
Review | New concepts in the treatment of hepatocellular carcinoma.
24 Aug, 2022 | 13:56h | UTCNew concepts in the treatment of hepatocellular carcinoma – UEG Journal
Long-term follow up of a RCT | Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine.
24 Aug, 2022 | 13:53h | UTCPrecancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Virological replacement & clinical unmasking are two phenomena of interest following #HPVvaccination. We show that clinical unmasking might attenuate long-term reductions in cervical precancer following successful implementation of HPV vax programs in highly screened populations https://t.co/Z7dGQNG1kG
— Monica Sierra (@MonicaSSierra) June 14, 2022
M-A | Incidence and mortality of non-AIDS-defining cancers among people living with HIV.
23 Aug, 2022 | 13:26h | UTCRelated: Study: Cancer Patients with HIV Infection Have Worse Outcomes
Case-control study | Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk.
23 Aug, 2022 | 13:11h | UTCCommentary: Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance — High-risk group had similar new lesion detection rates initially and at 15 months – MedPage Today (free registration required)
Commentary on Twitter
Among patients with a high risk of gastric cancer, 1-year surveillance was warranted even after intensive endoscopic examination using both white light and narrow-band imaging. https://t.co/3KIghTavjb
— JAMA Network Open (@JAMANetworkOpen) August 19, 2022
Single-arm Phase 2 study | Neoadjuvant chemotherapy, excision, and observation for early rectal cancer.
23 Aug, 2022 | 12:53h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share our @CDNCancerTrials NEO Trial results: 79% of patients with cT1-3bN0 #rectalcancer had organ sparing therapy with 3 mo of FOLFOX/CAPOX and transanal surgery. @drcarl_vancouvr @JCO_ASCO @OncoAlert https://t.co/gfcywHk7Y0
— Hagen Kennecke (@HKennecke) August 18, 2022
Consensus Recommendations | Standardizing pathologic evaluation of breast carcinoma after neoadjuvant chemotherapy.
23 Aug, 2022 | 12:52h | UTC
Spindle cell lesions of the breast: a diagnostic algorithm.
23 Aug, 2022 | 12:51h | UTC
M-A | Erlotinib plus bevacizumab vs. erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer.
22 Aug, 2022 | 12:04h | UTC
RCT | Effectiveness of Etoposide and Cisplatin vs. Irinotecan and Cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system.
22 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l
— JAMA Oncology (@JAMAOnc) August 18, 2022
Single-arm phase 2 study | Activity of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.
22 Aug, 2022 | 11:53h | UTCActivity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) – JAMA Oncology (free for a limited period)
Invited Commentary: Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet? – JAMA Oncology (free for a limited period)
Study | Almost half of global cancer deaths are due to risk factors, with smoking, alcohol use, and high BMI the greatest contributors.
19 Aug, 2022 | 16:21h | UTC
Commentary on Twitter (thread – click for more)
NEW #GBDstudy research from 2010-2019 found that a majority of attributable #Cancer DALYs globally were from behavioral risk factors. The top 3 behavioral risk factors for cancer burden were: #smoking 🚬, #alcohol 🍺, & high #BMI. @TheLancet »https://t.co/qPzDKzfLda pic.twitter.com/LnkvlkDHgA
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) August 18, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
Review | Barrett Esophagus.
17 Aug, 2022 | 14:26h | UTCBarrett Esophagus: A Review – JAMA (free for a limited period)
Audio clinical review: Barrett Esophagus – JAMA
ASCO Guideline Update | Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative.
17 Aug, 2022 | 14:17h | UTC
Systematic Review | Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
17 Aug, 2022 | 14:12h | UTC
Talking about dying: better conversations at the end of life.
17 Aug, 2022 | 14:14h | UTCTalking about dying: better conversations at the end of life – Evidently Cochrane
Original Reviews:
Commentary on Twitter
New @CochraneUK blog: @SarahChapman30 reflects on text conversations she had with her Mum’s carer when her Mum was dying during lockdown & explores recent evidence on good communication between health professionals, those who are dying & their families: https://t.co/WzA1Ff8jdF pic.twitter.com/fSlRyEOVym
— The Cochrane Library (@CochraneLibrary) August 16, 2022
M-A | Extent of tumor resection and survival in pediatric patients with high-grade gliomas.
17 Aug, 2022 | 14:00h | UTC
Commentary on Twitter
In this systematic review and meta-analysis of pediatric high-grade gliomas, gross total resection was associated with better overall survival than subtotal resection and biopsy. https://t.co/QpKiDKpYYs
— JAMA Network Open (@JAMANetworkOpen) August 16, 2022
M-A | Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials.
17 Aug, 2022 | 14:02h | UTC
Commentary on Twitter
Immunotherapy was associated with improved the quality of life of patients with advanced cancer, according to results of this comprehensive meta-analysis and systematic review of 34 RCTs of immune checkpoint inhibitors. https://t.co/uSLFT3Nuww
— JAMA Network Open (@JAMANetworkOpen) August 16, 2022
RCT | Chest CT scan plus x-ray vs. chest x-ray for the follow-up of completely resected non-small-cell lung cancer.
16 Aug, 2022 | 13:50h | UTCChest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Totally unexpected! After resection of early NSCLC in 1775 pts, follow-up by ct-scan did not improve survival vs a simple chest X-Rays! We should ALWAYS questioned our practice. Amazing work from Virginie Westeel @barlesi @IFCTlung https://t.co/iMFGtpkQcF
— Benjamin Besse (@BenjaminBesseMD) August 12, 2022
The contemporary management of cancers of the sinonasal tract in adults.
16 Aug, 2022 | 13:39h | UTC
Paraneoplastic encephalitis: clinically based approach on diagnosis and management.
16 Aug, 2022 | 13:19h | UTC
RCT | Adjuvant oral ibandronate does not improve outcomes in postmenopausal women with estrogen receptor–positive breast cancer.
16 Aug, 2022 | 13:15h | UTCDaily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
New phase 3 trial of adjuvant bisphosphonates for ER+ eBC published on @JCO_ASCO.
1,116 patients randomized to ET +/- 3 years of ibandronate. No DFS benefit (HR 0.97, p=0.81). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.https://t.co/CxhZcTNLhU— Paolo Tarantino (@PTarantinoMD) April 21, 2022
Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR.
15 Aug, 2022 | 11:44h | UTC
Phase 2 RCT | Biomarker-selected maintenance Poly ADP-Ribose Polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma.
15 Aug, 2022 | 11:42h | UTC
Single-center phase 2 trial | Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas.
11 Aug, 2022 | 11:52h | UTCDurvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK pic.twitter.com/BP7fz9FWRw
— The Lancet Oncology (@TheLancetOncol) August 5, 2022